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of the achieved LDL-C level on the stabilization of coronary plaques in the TWINS (evaluaTion With simultaneous angIoscopy and iNtravascular ultraSound) study.
Methods

Study Population
The subjects had CAD with hypercholesterolemia and had been enrolled in the TWINS study, 1 receiving lipid-lowering therapy with atorvastatin (10-20 mg/day) for 80 weeks. They started at an atorvastatin dose of 10 mg/day, and if the LDL-C level was ≥100 mg/dl at week 2, the daily dose was raised to 20 mg/day for the subsequent 78 weeks.
In the present sub-analysis, patients were divided into 2 groups by the median of LDL-C level at week 80 (low LDL-C group: LDL-C <91 mg/dl, and high LDL-C group: LDL-C ≥91 mg/dl). Then, the changes of angioscopic plaque color grade were assessed in relation to the LDL-C level. Angioscopic images of the coronary artery were taken at the start of the study and at week 28 and week 80 after treatment with atorvastatin ( Figure 1) .
The study protocol was approved by the Institutional Review Boards of Osaka Police Hospital and Nihon University Itabashi Hospital. All participants provided written informed consent before participation.
Angioscopic Examination
Angioscopy was done with a Fiber Imaging System FT-201 (FiberTech Co Ltd, Tokyo, Japan), with blood being cleared for viewing through an injection of 3% dextran-40, as previously reported. 6 The position of each plaque was confirmed using fluoroscopy to monitor the location of the fiberscope tip, and plaque maps were prepared based on the angioscopic findings. Yellow plaques were classified into six grades (0: no yellow, 1: pale yellow, 2: yellow, 3: deep yellow, 4: bright yellow, and 5: disrupted plaque) to evaluate the vulnerability, as previously reported. 1 The mean color grade was calculated for each patient, and changes to the color grade were compared before and after treatment in each group.
Angioscopic evaluation was performed by 2 independent investigators who were blinded to the background data of the patients and the timing of image acquisition. The interobserver reproducibility of interpretation of plaque color was 58.0% after the first evaluation. When the 2 observers did not agree, plaques were re-evaluated by the reviewers. The details of this procedure were previously described. 1 During this process, the investigators remained blind to the background data of the patients and the timing of image acquisition.
Statistical Analysis
Continuous variables are presented as mean ± SD. Fisher's exact test was performed to compare baseline characteristics of the patients between the 2 groups for categorical data and an unpaired t-test was used for numerical data. The Wilcoxon's signed-rank sum test was employed for the comparison of color grade between before and after treatment. In all analyses, P<0.05 (2-sided) was considered significant. For multiple comparison, Bonferroni's adjustment was applied. All statistical analysis were performed with the SAS statistical software package version 9.1 (SAS Institute Inc, Cary, NC, USA).
Results
Patient Population
As previously reported, 57 patients gave informed consent to participate in the TWINS study. 1 After the exclusion of 28 patients -10 consent withdrawal, 8 protocol deviation, 7 adverse events and 3 other reasons -29 had evaluable angioscopic data (Figure 2 ). The baseline characteristics of the 29 patients are shown in Table 1 ; 14 patients belonged to the low LDL-C group and 15 patients to the high LDL-C group. At the end of the study, 17 of these 29 patients were being treated with atorvastatin at 10 mg/day and 12 were receiving 20 mg/day. The mean age of the high LDL-C group was significantly older than that of the low LDL-C group. Other characteristics, including coronary risk factors and medications, showed no significant differences between the 2 groups.
Changes of Lipids and hsCRP Profile
In all 29 patients, the LDL-C level showed a decrease Table 2) ; and the median level in week 80 was 91 mg/dl. The lipid profiles of both low and high LDL-C groups were not significantly different at baseline. In both groups, LDL-C decreased significantly from baseline to week 80. By week 28, there was a significant reduction of total cholesterol and increase of highdensity lipoprotein cholesterol in both groups; but triglycerides were not significantly altered in either group. HsCRP did not differ between the 2 groups at baseline and did not change significantly by week 28. This trend continued to week 80 in both groups.
Angioscopic Findings
When the 2 groups were compared, angioscopic examination showed significant improvement of color grade in the low LDL-C group from baseline to week 28 and week 80 (1.44± 0.55 to 1.00±0.40 and 1.05±0.42; P=0.003 respectively); however, there was no significant change in the high LDL-C group from baseline to week 28 and week 80 (1.43±0.53 to 1.23±0.44 and 1.28±0.55; P=0.032 and P=0.143 respectively) (Figure 3) .
Discussion
For the secondary prevention of CAD, management of dyslipidemia is one of the most important factors. In the 2004 update of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) report, the recommended LDL-C target is <100 mg/dl for high-risk patients, including those hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol. Achieved LDL-C Level and Plaque Stabilization with a history of CAD, 7 and the optional target for very-highrisk patients is <70 mg/dl. Several angioscopic studies have suggested that the yellow color intensity of plaques is closely related to plaque vulnerability. 3, 8 We demonstrated in our previous study that atorvastatin treatment targeting an LDL-C level <100 mg/dl reduces the yellow color intensity (vulnerability) of plaques in CAD patients. 1
Achieved LDL-C Level and Angioscopic Findings
In the NCEP ATP III report, an LDL-C <70 mg/dl was included as a therapeutic option for very-high-risk patients. 7 Subsequent to that report, the TNT and IDEAL studies demonstrated that intensive statin therapy reducing LDL-C levels below 100 mg/dl is associated with better clinical outcomes than moderate statin therapy targeting LDL-C levels of about 100 mg/dl in patients with stable CAD. 9,10 In addition, the REVERSAL and ASTEROID trials showed that intensive statin therapy led to slower progression or even regression of the atheroma burden measured by IVUS. 11, 12 Statins have been reported to have pleiotropic effects in addition to reducing LDL-C levels and also reduced hsCRP in CAD patients. 13-15 However, no significant change in hsCRP was detected in the present study. Takano et al demonstrated a significant correlation between the change of the mean plaque yellow color intensity and the change of LDL-C levels from baseline to 12 months in patients with or without statin therapy. 16 However, the effect of intensive LDL-C reduction using statin therapy to the recommended ATP III target level (<100 mg/dl) has not been clarified before. 7 In the present study, the mean color grade of plaques was significantly reduced in low LDL-C group, but not in high LDL-C group. In the TOGETHAR trial, it was reported that evidence of plaque reduction had not been shown in IVUS because the decrease of LDL-C was small. The reduction of plaque-color intensity following treatment was not correlated with the LDL-C level. 17 However, in the TOGETHAR trial, the change in the plaque grade was also smaller than the result in patients of grade 2 or more in the TWINS sub-analysis (2.9±0.8 to 2.6±0.7 and 2.27±0.48 to 1.55±0.86 respectively), possibly because there was a difference in the patients' background and the evaluation method between 2 studies. 18 Additionally, the statin for pharmacological intervention was different from this study. A specific effect of the statins, but not a class effect, may contribute to the different results. These differences might influence the disagreement in results between the 2 studies. Therefore, more intensive reduction of lipid levels using statin therapy had a significantly better plaque-stabilizing effect. LDL-C level and color grade in week 28 were similar to those in week 80, as has been discussed in our previous report. 1 It is also suggested that plaque stabilization occurred relatively earlier than week 28. The achieved LDL-C levels of the low and high LDL-C groups in the present study (75.9 mg/dl and 99.1 mg/dl) were similar to the levels obtained for the intensive lipid-lowering therapy group and the other group in the TNT study (77 mg/dl and 101 mg/dl, respectively) and IDEAL study (81 mg/dl and 104 mg/dl, respectively). Therefore, our results support previous evidence that intensive lipid-lowering therapy provides a significant clinical benefit for patients with CAD. 9, 10 In conclusion, we have demonstrated that adequate reduction of LDL-C is important for the stabilization of coronary plaques using atorvastatin treatment in CAD patients. It will be necessary to confirm our results through prospective analysis with increasing the number of cases in the future.
Study Limitations
The angioscopic evaluation of plaque color is subjective. We analyzed retrospectively, not prospectively, the influence of achieved LDL-C level on stabilization of coronary plaques. The number of patients was small, so we could not conduct multivariate analysis to assess the influence of other factors such as age.
Conclusion
Adequate reduction of LDL-C is important for the stabilization of coronary plaque using atorvastatin treatment in CAD patients.
